Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RNA-based Therapy
Therapeutic Area : Nephrology
Study Phase : Preclinical
Sponsor : Atlas Venture
Deal Size : $100.0 million
Deal Type : Series A Financing
Judo Bio Debuts with $100M and To Take RNA Drugs to The Kidney
Details : The proceeds from the financing will be used to advance the lead ligand-siRNA conjugate to the clinic and to further build the proprietary STRIKE platform for the treatment of kidney diseases.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 07, 2024
Lead Product(s) : RNA-based Therapy
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Sponsor : Atlas Venture
Deal Size : $100.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?